Oramed Pharmaceuticals (ORMP) Competitors $2.24 +0.01 (+0.45%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. ITOS, RVNC, FULC, CKPT, VIGL, RZLT, ARCT, ADCT, RAPP, and ORGOShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Fulcrum Therapeutics (FULC), Checkpoint Therapeutics (CKPT), Vigil Neuroscience (VIGL), Rezolute (RZLT), Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Rapport Therapeutics (RAPP), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors iTeos Therapeutics Revance Therapeutics Fulcrum Therapeutics Checkpoint Therapeutics Vigil Neuroscience Rezolute Arcturus Therapeutics ADC Therapeutics Rapport Therapeutics Organogenesis iTeos Therapeutics (NASDAQ:ITOS) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends. Which has more volatility & risk, ITOS or ORMP? iTeos Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Does the MarketBeat Community believe in ITOS or ORMP? Oramed Pharmaceuticals received 270 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 73.13% of users gave iTeos Therapeutics an outperform vote while only 71.85% of users gave Oramed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformiTeos TherapeuticsOutperform Votes4973.13% Underperform Votes1826.87% Oramed PharmaceuticalsOutperform Votes31971.85% Underperform Votes12528.15% Do insiders and institutionals believe in ITOS or ORMP? 97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, ITOS or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than iTeos Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiTeos Therapeutics$35M10.91-$112.64M-$3.04-3.28Oramed Pharmaceuticals$2M45.75$5.53M-$0.44-5.09 Is ITOS or ORMP more profitable? Oramed Pharmaceuticals' return on equity of -7.27% beat iTeos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets iTeos TherapeuticsN/A -20.11% -17.50% Oramed Pharmaceuticals N/A -7.27%-6.20% Do analysts rate ITOS or ORMP? iTeos Therapeutics currently has a consensus target price of $15.86, indicating a potential upside of 58.89%. Given iTeos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe iTeos Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ITOS or ORMP? In the previous week, iTeos Therapeutics had 23 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 24 mentions for iTeos Therapeutics and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat iTeos Therapeutics' score of 0.15 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment iTeos Therapeutics Neutral Oramed Pharmaceuticals Very Positive SummaryOramed Pharmaceuticals beats iTeos Therapeutics on 10 of the 17 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$91.10M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio20.368.6727.1819.96Price / Sales45.75262.53412.23157.63Price / CashN/A65.8538.2534.64Price / Book0.556.597.064.69Net Income$5.53M$143.75M$3.23B$248.14M7 Day Performance0.90%0.82%0.80%0.95%1 Month PerformanceN/A12.09%9.71%5.74%1 Year Performance-1.97%4.46%32.11%14.73% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.8717 of 5 stars$2.24+0.4%N/A-3.9%$91.10M$2M20.3610ITOSiTeos Therapeutics3.8723 of 5 stars$10.01-0.1%$15.86+58.4%-39.4%$383.12M$35M-3.1890Insider TradeHigh Trading VolumeRVNCRevance Therapeutics2.5924 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500FULCFulcrum Therapeutics0.4333 of 5 stars$6.96+1.2%$6.29-9.7%-12.1%$375.69M$80M-22.45100Analyst RevisionCKPTCheckpoint Therapeutics2.5515 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210VIGLVigil Neuroscience4.0629 of 5 stars$7.93+0.5%$10.80+36.2%+68.9%$370.11MN/A-3.8540Positive NewsRZLTRezolute2.7219 of 5 stars$4.22+2.4%$12.14+187.7%-19.7%$360.89MN/A-3.4640Positive NewsHigh Trading VolumeARCTArcturus Therapeutics3.2631 of 5 stars$12.81+2.2%$53.50+317.6%-59.3%$347.42M$131.27M-5.77180Analyst RevisionGap UpADCTADC Therapeutics2.8633 of 5 stars$3.50+13.3%$7.75+121.3%+15.8%$347.32M$75.82M-1.47310News CoveragePositive NewsAnalyst RevisionGap DownHigh Trading VolumeRAPPRapport Therapeutics1.7583 of 5 stars$9.40+13.7%$32.67+247.5%N/A$343.08MN/A-2.72N/APositive NewsHigh Trading VolumeORGOOrganogenesis4.6327 of 5 stars$2.66-2.9%$5.50+106.8%+20.1%$337.43M$458.76M-44.33950Positive NewsAnalyst Revision Related Companies and Tools Related Companies iTeos Therapeutics Competitors Revance Therapeutics Competitors Fulcrum Therapeutics Competitors Checkpoint Therapeutics Competitors Vigil Neuroscience Competitors Rezolute Competitors Arcturus Therapeutics Competitors ADC Therapeutics Competitors Rapport Therapeutics Competitors Organogenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts